1Which structures are involved in a superficial incisional SSI?
skin or subcutaneous tissue of the incision
2Which structures are involved in a deep incisional SSI?
fascia and/or muscular layers
3What does an organ or space SSI involve?
any space or organ, opened or manipulated during the procedure
4What is the main source of organisms causing SSIs?
the microbiome of the patient’s skin or nares
5Which organisms are among the most common SSI pathogens?
S aureus, coagulase-negative staphylococci, Streptococci spp, Enterococcus spp, and E coli
6What preoperative glucose goal is listed for patients with diabetes?
110-150 mg/dL
7When should prophylactic antibiotics generally be administered before surgery?
within 1 hour before surgery
8When should vancomycin or fluoroquinolone prophylaxis be administered?
within 2 hours before surgery
9What cephalosporin is described as having very low cross-reactivity with penicillin?
cefazolin
10What is the preoperative S. aureus nasal decolonization regimen?
mupirocin 2% ointment twice daily for up to 5 days before surgery
11What is the recommended antiseptic for surgical skin preparation?
Alcohol-based antiseptic solutions with chlorhexidine gluconate
12What combination is recommended for colorectal bowel preparation?
oral antibiotic prophylaxis and mechanical bowel preparation
13When should surgical prophylaxis be redosed based on antibiotic half-life?
2 times the half-life of the agent
14When is prophylactic antibiotic redosing indicated beyond elapsed time?
significant intraoperative blood loss
15When should prophylactic antibiotics end after non-cardiac surgery?
within 24 hours after non-cardiac surgery
16When should prophylactic antibiotics end after cardiac surgery?
within 48 hours after cardiac surgery
17What cefazolin surgical prophylaxis dose is given at weight ≥120 kg?
3 g for patients weighing ≥ 120 kg
18What is the cefazolin redosing interval (hours)?
4
19What is the standard surgical prophylaxis dose of clindamycin?
900 mg
20What is the surgical prophylaxis dose of vancomycin?
15 mg/kg
21What is the surgical prophylaxis dose of gentamicin?
5 mg/kg of ideal or adjusted body weight
22What is the formula for adjusted body weight?
IBW + 0.4 (actual weight − IBW)
23What is the surgical prophylaxis dose of metronidazole?
500 mg
24What is the surgical prophylaxis dose of ceftriaxone?
2 g
25Which agent is the recommended prophylaxis for most cardiac and vascular surgeries?
Cefazolin
26Under CDC surveillance criteria, how long must a urinary catheter have been in place?
> 2 days
27When must a removed catheter have been present for a CDC-defined CAUTI?
the day before the event
28What urine culture threshold is shown for CDC-defined CAUTI?
Positive urine culture > 10^5 CFU/mL
29How many species may grow in the CDC CAUTI urine culture?
no more than two species of organisms
30What colony count defines asymptomatic bacteriuria in the IDSA definition?
greater than 10^5 CFU/mL
31What colony count defines a symptomatic CAUTI by the IDSA definition?
10^3 CFU/mL or more
32How long after catheter removal does IDSA include symptomatic CAUTI?
within the previous 48 hours
33What is the most prevalent pathogen causing CAUTIs?
E coli
34What is the most effective approach to CAUTI prevention?
minimize the use of urinary catheters
35When should postoperative urinary catheters be removed if possible?
within 24 hours postoperatively
36Which practice is NOT recommended for preventing CAUTI?
NOT recommended: Routine screening or treatment of asymptomatic bacteriuria
37What is NOT recommended solely because a urinary catheter is placed?
NOT recommended: Use of systemic antibiotic prophylaxis solely due to catheter placement
38What drainage-bag practice should NOT be used to prevent CAUTI?
NOT recommended: Addition of antibiotics to drainage bag
39How many days must a central line be present for the CDC CLABSI definition?
more than 2 days
40Which clinical findings satisfy CDC bloodstream infection symptoms with common skin flora?
temperature greater than 100.4°F [38°C], chills, hypotension
41What cultures establish definitive catheter-related bloodstream infection by IDSA?
same organism or organisms grow from at least 1 percutaneous blood culture and from the CVC tip
42What other paired cultures can establish catheter-related bloodstream infection?
1 from a catheter hub and 1 from a peripheral vein
43What organisms commonly cause CLABSIs?
coagulase-negative staphylococci (e.g., S epidermidis), S aureus, Candida spp, and enteric gram-negative bacilli
44What parenteral nutrition exposure increases Candida CLABSI risk?
total parenteral nutrition
45Which site has lower CLABSI risk than the IJ or femoral sites?
subclavian vein
46What skin cleanser is recommended for central-line insertion?
Alcohol-based chlorhexidine skin cleanser
47What bathing intervention is part of CLABSI prevention?
Daily chlorhexidine baths
48What dressing is part of essential CLABSI prevention practices?
Chlorhexidine-containing site/catheter dressings
49Should routine systemic antibiotics be used to prevent CLABSI?
Do not use systemic antibiotic prophylaxis.
50When can antibiotic lock therapy be considered for central lines?
patients with limited venous access or a history of catheter-related bloodstream infections
51What CSF glucose value is a strong predictor of bacterial meningitis?
CSF glucose less than 40 mg/dL
52What CSF-to-blood glucose ratio suggests bacterial meningitis?
less than 0.6
53Which culture is most specific for health care-associated meningitis?
CSF culture
54When should empiric antimicrobials be initiated for suspected bacterial meningitis?
as soon as possible after bacterial meningitis is suspected
55Which pathogen has the clearest benefit from adjunctive dexamethasone?
Streptococcus pneumoniae
56What is the recommended adjunctive dexamethasone dose in bacterial meningitis?
0.15 mg/kg every 6 hours for up to 96 hours
57When is the first dexamethasone dose given in meningitis?
10–20 minutes before, or at least concomitant with, the first dose of antimicrobial therapy
58What is recommended for an infected CSF shunt?
complete removal of an infected CSF shunt and replacement with an external ventricular drain
59How long should external ventricular drains be clamped after intraventricular antibiotics?
15-60 minutes
60What formulation requirement applies to intraventricular antibiotics?
preservative free
61What CSF antibiotic concentration target is given for intraventricular therapy?
10-20 times the MIC
62What is the minimum duration of therapy for meningitis in general?
at least 7 days
63What meningitis duration is recommended for pneumococcus, staphylococci and gram-negative bacilli?
10–14 days
64What meningitis duration is recommended for Listeria?
at least 21 days
65How long should CSF be negative for S. aureus before shunt replacement?
at least 10 days
66What empiric regimen is listed for community-acquired meningitis, age 18–50?
Vancomycin + third-generation cephalosporin
67What is added to empiric meningitis therapy for age over 50 or predisposing condition?
ampicillin
68What empiric regimen covers meningitis after neurosurgery?
Vancomycin + cefepime or ceftazidime or meropenem
69What is the ampicillin dose listed for meningitis?
2 g IV q4hr
70What is the ceftriaxone dose listed for meningitis?
2 g IV q12hr
71What is the cefepime dose listed for meningitis?
2 g IV q8hr
72What is the meropenem dose listed for meningitis?
2 g IV q8hr
73What is the vancomycin intraventricular dose listed?
10–20 mg once daily
74Why is piperacillin/tazobactam not recommended for meningitis?
low penetration of tazobactam
75What is the goal of antibiotic stewardship?
optimize clinical outcomes while minimizing unintended consequences of antimicrobial use
76What does antibiotic stewardship seek to improve?
selection of optimal antimicrobial drug regimen, including dosing, duration, and route of administration
77Which two adverse outcomes are antimicrobial stewardship programs intended to minimize?
antimicrobial resistance and adverse drug reactions
78What tracking metric is specifically cited in the TJC stewardship standards?
days of therapy per 1000 days present or 1000 patient-days
79What two primary stewardship review strategies are recommended by TJC?
preauthorization for specific antibiotics and/or prospective review and feedback
80What stewardship strategy involves shortening therapy and stopping unnecessary drugs?
Streamlining or de-escalation of therapy
81Which antibiotics have IDSA-recommended PK and dose monitoring programs?
vancomycin and aminoglycosides
82What route change is an ASP core activity?
Parenteral to oral conversion
83What educational approach does IDSA recommend against as a standalone stewardship strategy?
didactic education alone
84What is the back-end antimicrobial stewardship strategy?
Prospective audit with intervention and feedback
85What is the front-end antimicrobial stewardship strategy?
Formulary restriction and preauthorization
86What strategy involves scheduled antimicrobial substitution and is not recommended by IDSA?
Antimicrobial cycling
87What process metrics can evaluate a stewardship program?
days of therapy, provider adherence to clinical pathway, time to effective therapy
88What outcome metrics can evaluate a stewardship program?
LOS, mortality, 30-day readmission
89What happens to mortality with ICU prospective audit and feedback according to meta-analyses?
no increase in mortality
90How long can traditional pathogen identification and susceptibility testing take?
72–96 hours
91Within what time are rapid blood-culture tests meant to offer actionable information?
the first 24 hours from the time of culture positivity
92What common limitation affects many rapid diagnostic techniques?
inability to detect polymicrobial infections
93What advantage can pathogen detection directly from whole blood provide?
identify bacteria in patients with recent or current antibiotic exposure
94What molecular target does PNA FISH identify?
species-specific ribosomal RNA
95What is the reported sensitivity and specificity of PNA FISH?
96%–100%
96What does PNA FISH not provide?
antimicrobial sensitivity data
97Which rapid method distinguishes S. aureus from coagulase-negative staphylococci?
PNA FISH
98What does MALDI-TOF stand for?
Matrix-assisted laser desorption-ionization/time of flight
99What is the sensitivity and specificity of MALDI-TOF?
98%–100%
100What key susceptibility information does MALDI-TOF not generally provide?
no antimicrobial susceptibility is reported
101Which gene is targeted by MRSA PCR?
mecA gene
102What is the key stewardship use of MRSA PCR?
Earlier de-escalation of anti-MRSA antimicrobials
103What is the reported MRSA PCR negative predictive value in the chapter?
98%
104Which resistance genes are detected by described multiplex PCR methods?
mecA - methicillin resistance; van A/B - vancomycin resistance
105What type of technology is the Verigene blood-culture test?
Nanoparticles (Microarray)
106What is the range of sensitivity and specificity for Verigene testing?
93%–100%
107What is the BioFire PCR turnaround time after a positive blood culture?
1 hr
108Which gene indicates methicillin-resistant S. aureus in the rapid diagnostic treatment table?
mecA-positive
109What is the preferred treatment for mecA-positive S. aureus in Table 6?
Vancomycin
110What is the preferred treatment for mecA-negative S. aureus in Table 6?
Nafcillin
111What is the recommended treatment for vanA/B-positive E. faecium in Table 6?
Daptomycin
112Which drug group is recommended for CTX-M-producing Enterobacterales in Table 6?
Carbapenems (ertapenem, imipenem, meropenem)
113Which test detects C. difficile toxin A or B genes?
Nucleic acid amplification methods
114What is the reported sensitivity and specificity of rapid C. difficile PCR tests?
90%–96%
115Why can repeated rapid C. difficile PCR testing be problematic?
only furthers the chance of false positivity
116Why can blood cultures fail to detect invasive candidiasis?
negative blood cultures
117Which three fungal pathogens can serum β-d-glucan detect?
Candida, Aspergillus, and Pneumocystis
118What are the reported T2 Candida sensitivity and specificity?
High sensitivity (91%) and specificity (98%)
119What biomarker is specific to Candida spp.?
Mannan
120Which fungal pathogen produces galactomannan?
Aspergillus spp.
121What does procalcitonin reflect?
host response to bacterial infections
122How quickly is PCT released after exposure to bacterial toxins?
within 2–4 hours
123What is the plasma half-life of PCT?
24 hours
124What is the usual PCT concentration in healthy patients?
less than 0.05 mcg/L
125Which chronic condition may raise baseline PCT?
Chronic kidney disease
126Should low PCT be used alone to withhold antibiotics in suspected sepsis?
the recommendation to withhold antimicrobials when the PCT was low
127How should low or falling PCT be used during treatment?
shorten the duration of antimicrobial therapy
128How does PCT guidance affect antibiotic duration in the cited largest trial?
median 5 days vs. 7 days
129What PCT reduction by day 4 was associated with prognostic information?
at least 80% by day 4
130Which PCT value suggests antibiotic cessation in the sample algorithm?
PCT < 0.25 mcg/L
131What PCT fall from peak supports stopping antibiotics in the sample algorithm?
Decrease by ≥ 80%
132What PCT level with inadequate decline supports continuing antibiotics?
PCT ≥ 0.5 mcg/L
133What score range on the host response diagnostic is interpreted as viral infection?
0–34 = viral infection
134What score range on the host response diagnostic is interpreted as bacterial infection?
66–100 = bacterial infection
135Which organization determines MIC breakpoint standards?
Clinical & Laboratory Standards Institute (CLSI)
136What is the qualitative output of Kirby-Bauer disk diffusion?
sensitive, intermediate, or resistant
137How is inhibition-zone diameter related to MIC in disk diffusion?
inversely proportional to the MIC value
138Which susceptibility method uses serial twofold antibiotic dilutions?
Dilution methods
139What susceptibility method uses a calibrated plastic strip?
E-test
140How is an MIC identified using an E-test strip?
intersection between the zone of inhibition and the edge of the calibrated strip
141Which test detects inducible clindamycin resistance?
double-disk diffusion
142Can routine AST detect inducible macrolide-lincosamide-streptogramin resistance?
not detected by routine AST
143Which antibiotic inhibitor confirms ESBL activity in confirmatory testing?
clavulanic acid
144What MIC decrease after clavulanic acid confirms ESBL activity?
three 2-fold dilution decreases
145What is the updated ceftriaxone susceptibility cutoff for Enterobacterales in Table 7?
≤ 1
146What is the updated cefazolin susceptibility cutoff for non-UTI infections in Table 7?
≤ 2
147What agent used in confirmatory testing inhibits zinc-mediated MBL?
ethylene-diamine tetraacetic acid
148What KPC screening clue is especially sensitive on AST?
Ertapenem resistance
149What carbapenem MIC in an Enterobacterales should prompt KPC evaluation?
1 mcg/mL or greater
150What mismatch can lead labs to report susceptible results despite current CLSI resistance criteria?
FDA labeling may not be up to date with the current CLSI recommendations
151What administration strategy can optimize beta-lactam PK/PD when MIC is high?
extended- or continuous-infusion β-lactams
152What other options may optimize therapy when MICs are challenging?
using a higher dose
153Which Enterobacterales resistance is an urgent CDC threat?
Carbapenem-resistant Enterobacterales
154Which fungal pathogen is also a CDC urgent resistance threat?
Candida auris
155Which staphylococcal pathogen is listed as a serious resistance threat?
MRSA
156What mechanisms produce beta-lactam resistance in Table 9?
β-Lactamases (AmpC, ESBL, KPC)
157What resistance mechanism affects fluoroquinolone target proteins?
Altered DNA gyrase and topoisomerase
158What enzyme alteration is associated with trimethoprim resistance?
Altered dihydrofolate reductase
159Which resistance mechanism reduces antibiotic entry into bacteria?
Decreased permeability
160What is another bacterial resistance mechanism involving pumps?
Increased efflux
161What resistance mechanism includes altered penicillin binding proteins?
Target modification
162What bacterial resistance mechanism involves beta-lactamases?
Hydrolysis
163What is colonization pressure?
Proportions of people colonized with resistant bacteria
164What drugs are hydrolyzed by ESBL-producing pathogens?
third-generation cephalosporins and aztreonam
165Which species most commonly produce ESBLs in the chapter?
E. coli and K. pneumoniae spp.
166What is the preferred treatment class for severe ESBL infections?
Carbapenems
167What trial mortality comparison is provided for PTZ versus meropenem in ceftriaxone-resistant bloodstream infection?
12.3% vs. 3.7%
168What does the ESBL evidence suggest about piperacillin-tazobactam?
do not support the use of piperacillin/tazobactam
169What cefepime MIC is noted as a possible consolidation-therapy option in stable ESBL infection?
1 mcg/mL or less
170What cefepime MIC range represents susceptible dose-dependent for Enterobacterales?
4 and 8 mcg/mL
171For which infection did cefepime-enmetazobactam receive FDA approval?
complicated UTIs including pyelonephritis
172Which carbapenemases are NOT covered by cefepime-enmetazobactam?
KPC, metallo-β-lactamases, or some oxacillinases
173What antibiotics do AmpC enzymes confer resistance to?
penicillins and narrow-spectrum cephalosporins
174Do tazobactam and clavulanate add coverage against AmpC?
tazobactam and clavulanic acid would not provide additional coverage
175What bacterial species are associated with AmpC inducibility?
Enterobacter, Citrobacter, Serratia, Morganella, Providencia, and Pseudomonas
176What happens when AmpC is derepressed?
resistance to third-generation cephalosporins and broad-spectrum penicillins
177Which cephalosporin generally retains activity against AmpC derepressed mutants?
Cefepime
178What two options are listed for severe AmpC infections?
Carbapenem and cefepime
179Which bacterial groups can express carbapenemase?
Acinetobacter, Pseudomonas, and Enterobacterales
180Which glycylcycline inhibits the 30S ribosomal subunit?
Tigecycline
181Which important gram-negative pathogens are not covered by tigecycline?
Pseudomonas, Providencia, Proteus, or Morganella
182Why is tigecycline generally avoided for UTIs?
Urinary elimination is 8%–11%
183What PK property raises concerns about tigecycline for bacteremia?
Wide volume of distribution: 7–10 L/kg
184Which infection had lower tigecycline treatment success compared with imipenem?
hospital-acquired pneumonia
185What FDA safety warning was issued for tigecycline?
possible increased mortality risk
186What pathogens do polymyxins NOT cover?
Proteus, Providencia, Burkholderia, Serratia, or Stenotrophomonas
187What is the prodrug administered in colistin preparations?
colistimethate
188Which active compound results from hydrolysis of colistimethate?
colistin
189What is the PK/PD index of colistin activity?
area under the curve/MIC ratio
190How many colistin IU correspond to ~100 mg colistin-based activity?
3 million IU
191What is the international consensus colistin loading dose?
300 mg colistin base activity loading dose
192What is the international consensus colistin maintenance dose?
300-360 mg colistin base activity divided every 12 hours
193What is the international consensus polymyxin B loading dose?
2–2.5 mg/kg total body weight
194What is the international consensus polymyxin B maintenance dose?
1.25–1.5 mg/kg total body weight every 12 hours
195Which polymyxin is preferred for routine systemic use?
Polymyxin B
196Which polymyxin is preferred for UTIs?
Colistin
197What is the primary dose-limiting adverse effect of polymyxins?
Nephrotoxicity
198Which KPC-producing organisms are treated with ceftazidime/avibactam?
KPC-producing Enterobacterales
199Which resistance enzyme group is not meaningfully inhibited by ceftazidime-avibactam?
metallo-β-lactamase-expressing strains
200What carbapenemase class does vaborbactam inhibit?
class A carbapenemases, including KPC
201Does meropenem/vaborbactam expand coverage against carbapenem-resistant Pseudomonas?
It is not found to expand coverage to carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, or Stenotrophomonas maltophilia.
202Which enzyme does cilastatin inhibit?
dehydropeptidase-1
203Which resistant organisms are targeted clinically by imipenem-relebactam?
KPC-producing Enterobacterales
204What is cefiderocol's bacterial uptake mechanism?
bacterial iron transport systems
205What common phrase describes cefiderocol's mechanism?
“Trojan Horse” strategy
206Which gram-negative organisms does cefiderocol cover?
Enterobacterales, Pseudomonas, Acinetobacter, and Stenotrophomonas
207Does cefiderocol have meaningful gram-positive activity?
no clinically relevant in vitro activity
208Which beta-lactamase groups can cefiderocol resist?
serine (including KPCs and OXA-48) and metallo-β-lactamases
209Which antibiotic combination was specifically developed for CRAB?
Sulbactam/durlobactam
210Which component of sulbactam/durlobactam has intrinsic Acinetobacter activity?
Sulbactam
211What drug is highlighted for difficult-to-treat multidrug-resistant Pseudomonas?
Ceftolozane/tazobactam
212What higher ceftolozane/tazobactam dose was evaluated for hospital-acquired/VAP?
3 g every 8 hours
213Which aminoglycoside dose is recommended for expanded Pseudomonas coverage?
tobramycin 7 mg/kg every 24 hours
214Which aminoglycoside is no longer recommended for Pseudomonas?
Gentamicin
215Which two treatments are discussed for MRSA bacteremia?
vancomycin or daptomycin
216What daptomycin dose was used in the right-sided endocarditis study?
6 mg/kg
217What higher daptomycin doses do some experts use?
8–10 mg/kg
218What treatments are options for community-acquired MRSA pneumonia?
vancomycin or linezolid
219What is the AUC monitoring guideline target for vancomycin?
AUC
220What is the role of tedizolid in critical care?
Place in therapy among critically ill patients is limited
221What vancomycin AUC24 target is recommended for serious MRSA infection?
400–600 mg/hour/L
222Are trough-only targets still recommended for serious MRSA infection?
Trough targets are no longer recommended
223What method is recommended for vancomycin dose adjustments?
Bayesian dosing
224What is the oral/IV daily dose of tedizolid?
200 mg once daily
225What drug class is tedizolid?
Oxazolidinone
226Which PVL-associated clinical syndrome is linked to community-acquired MRSA?
necrotizing pneumonia
227What single oral temperature defines fever in febrile neutropenia?
101°F (38.3°C) or greater
228What sustained oral temperature defines fever in neutropenia?
100.4°F (38.0°C) or greater orally for more than 1 hour
229What ANC defines neutropenia in this chapter?
Less than 500 neutrophils/mm3
230What MASCC score signals low-risk febrile neutropenia?
21 or greater
231What MASCC score signals high-risk febrile neutropenia?
less than 21
232What ANC level is a high-risk criterion for febrile neutropenia?
less than 100 neutrophils/mm3
233What expected duration of neutropenia signals high risk?
longer than 7 days
234What initial antibiotic regimen is recommended in high-risk febrile neutropenia?
monotherapy with an intravenous antipseudomonal β-lactam
235What initial options are listed for febrile neutropenia with type I beta-lactam hypersensitivity?
ciprofloxacin or aztreonam plus vancomycin
236When should dual gram-negative coverage be considered in neutropenic fever?
patients with shock or if antimicrobial resistance is suspected
237When is empiric vancomycin indicated in febrile neutropenia?
shock, suspected catheter-related infection, skin and soft tissue infection, pneumonia, and/or hemodynamic instability
238When can empiric gram-positive coverage be stopped if no infection is found?
48–72 hours
239When should empiric antifungal therapy be considered in persistent neutropenia?
4–7 days after initiation of antibacterial agents
240What ANC indicates recovery before stopping treatment for febrile neutropenia?
ANC greater than 500 cells/mm3
241How long must patients be afebrile before treatment cessation?
at least 48 hours
242Should hematopoietic growth factors routinely be used to treat febrile neutropenia?
should not be used for the treatment of febrile neutropenia
243At what anticipated febrile neutropenia risk should growth-factor prophylaxis be considered?
20% or greater
244When are most infections seen after solid organ transplant?
first 6 months after transplantation
245Why are opportunistic infections uncommon in the first posttransplant month?
full effects of immunosuppression are not yet present
246What usually causes viral/fungal infection in the first posttransplant month?
donor derived
247Who should be consulted if severe infection requires reduced immunosuppression?
transplant team
248What can cause low CD4 counts in patients without HIV?
Critical illness
249What is immune reconstitution inflammatory syndrome (IRIS)?
Unexpected worsening of existing OI or unmasking of previously unrecognized illness
250What HIV treatment change is linked to IRIS?
recent HAART initiation
251What risk factor for IRIS is related to baseline viral burden?
High baseline HIV viral load
252What treatment is suggested for severe IRIS requiring vasopressors or ventilation?
prednisone
253If one antiretroviral must be interrupted, what is generally recommended?
all of the therapies should be discontinued
254Why can simultaneous NNRTI discontinuation cause resistance?
a period of functional NNRTI monotherapy
255What NRTI complication is associated with mitochondrial toxicity?
lactic acidosis
256Which older NRTIs are associated with lactic acidosis?
zidovudine, stavudine, and didanosine
257What pharmacogenomic allele predicts abacavir hypersensitivity?
HLA-B*5701
258What must never be done after abacavir hypersensitivity?
rechallenge contraindicated
259What serious adverse effect is associated with raltegravir?
rhabdomyolysis
260What important serious toxicities are associated with tipranavir?
hepatotoxicity and intracranial hemorrhage
261When is P. jirovecii prophylaxis indicated by CD4 count?
< 200 cells/mm3
262What CD4 percentage threshold is listed for PJP prophylaxis?
< 14%
263What is the preferred PJP prophylaxis regimen?
TMP/SMX 1 DS PO daily
264What is the TMP-SMX treatment dose and duration for PJP?
15–20 mg/kg PO/IV divided q6–8hr x 21 days
265At what PaO2 is adjunctive PJP prednisone indicated?
Pao2 < 70 mm Hg
266At what A–a gradient is adjunctive PJP prednisone indicated?
alveolar-arterial O2 gradient > 35
267What is the initial prednisone dose for moderate/severe PJP?
prednisone 40 mg PO q12hr x 5 days
268What is the prednisone dose on days 6–10 for PJP?
40 mg/day x 5 days
269What is the prednisone dose on days 11–21 for PJP?
20 mg/day x 11 days
270What methylprednisolone conversion is used in PJP?
75% of the corresponding oral prednisone dose
271Which HIV patients need toxoplasmosis prophylaxis?
< 100 cells/mm3 and Toxoplasma IgG positive
272What is the preferred toxoplasmosis prophylaxis?
TMP/SMX 1 DS PO daily
273What is the preferred toxoplasmosis treatment combination?
Pyrimethamine + sulfadiazine + leucovorin
274How long is toxoplasmosis induction therapy given?
6 wk
275What CD4 count is associated with MAC prophylaxis consideration?
< 50 cells/mm3
276When may MAC prophylaxis be needed at CD4 <50?
not receiving antiretroviral therapy (ART)
277What is the preferred MAC prophylaxis dose of azithromycin?
Azithromycin 1200 mg once weekly
278What is the core treatment combination for MAC?
Clarithromycin or azithromycin plus ethambutol
279What is preferred for cryptococcal meningitis induction?
Liposomal amphotericin IV 3-4 mg/kg/day + flucytosine
280How long is cryptococcal meningitis induction treatment?
2 wk
281What is cryptococcal meningitis consolidation treatment?
Fluconazole PO/IV 400 mg/day
282How long is cryptococcal meningitis consolidation?
8 wk
283What is cryptococcal meningitis maintenance dose?
Fluconazole PO/IV 200 mg/day
284How long is cryptococcal meningitis maintenance therapy?
1 yr
285What is an option for CMV induction treatment?
Ganciclovir 5 mg/kg q12hr for 14–21 days
286What is the oral induction regimen for CMV?
Valganciclovir PO 900 mg BID for 14–21 days
287What is an alternative drug for treatment of resistant CMV?
Foscarnet
288What drug is coadministered with cidofovir to limit toxicity?
probenecid
289What interaction occurs between rilpivirine and proton-pump inhibitors?
Contraindicated with proton pump inhibitors
290What is the interaction of ritonavir-boosted protease inhibitors with rivaroxaban?
Do not coadminister
291What is the apixaban recommendation with boosted protease inhibitors at 2.5 mg BID?
Do not administer in patients who require 2.5 mg BID
292What is the mechanism of action of amphotericin B?
Binds to ergosterol in the fungal cell membrane
293Which Candida species is excluded from amphotericin's usual spectrum?
C. lusitaniae
294What is the conventional amphotericin B dose?
0.5–1.0 mg/kg/day
295What is the lipid amphotericin B dose?
3–5 mg/kg/day
296Which electrolytes may be wasted with amphotericin B?
Potassium, magnesium, phosphate
297What saline loading approach is listed to limit amphotericin nephrotoxicity?
500 mL of normal saline before and after infusion of amphotericin
298What premedication timing is listed for amphotericin infusion reactions?
30–60 minutes before infusion
299Which medication may be used for amphotericin-associated rigors?
Meperidine 25–50 mg intravenously
300What is the mechanism of action of triazole antifungals?
blocking the CYP enzyme 14-α-sterol-demethylase